Handelsavisen
prelaunch
Companies Healthcare BAX.HN
BA
BAX.HN Diversified Medical Equipment & Supplies

Thong Nhat JSC

$1,53
Open in Charts → Attach watcher ⌖
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
P/E
EV / Rev
Div yield
7,51 %
Op margin
59,2 %
ROE
4,0 %
Net margin
47,3 %
Debt / equity
0,00
Beta
52w range
Volume
Day range
Prev close
$26,75
Open
$27,00
Next earnings
2026-09-09
Ex-dividend
TR 1Y
About

Thong Nhat JSC operates in the real estate rental, development, and operations sector, generating revenue primarily through property development and management activities.

Business. Thong Nhat JSC (BAX.HN) is a real estate company engaged in rental, development, and operations activities. The firm generates revenue primarily through rental income within the Real Estate sector. Specific details regarding operating segments, headquarters location, and primary exchange listings are not available in the provided data. Consequently, the company is described at the industry level without geographic or segment breakdowns.

Classification99 %
SectorHealth Care
Industry groupDiversified Medical Equipment & Supplies
Generated · model-assisted
Sell-side consensus
HOLD17 analysts
2 buy13 hold2 sell
Avg 12m price target21,19

Analyst recommendations

17 analysts · consensus Hold
Buy2
Hold13
Sell2
12-month price target
21,19
Consensus of sell-side coverage.
Upcoming events
  • EarningsQ2 2026 earnings (confirmed · filed)2026-09-09
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
Hold
17 analysts · indicative
Ownership
Dodge & Cox
largest disclosed fund holder
Profitability
4,0 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning BAX.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to BAX.HN. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    Thong Nhat JSC (BAX.HN) is a real estate company engaged in rental, development, and operations activities. The firm generates revenue primarily through rental income within the Real Estate sector. Specific details regarding operating segments, headquarters location, and primary exchange listings are not available in the provided data. Consequently, the company is described at the industry level without geographic or segment breakdowns.

    Classification99 %
    SectorHealth Care
    Industry groupDiversified Medical Equipment & Supplies
    AI synthesis
    GENERATED

    Thong Nhat JSC maintains a strong liquidity position, with a current ratio of 7.43, indicating a significant buffer of current assets over current liabilities. The company's cash and equivalents amount to VND 22.8 billion, contributing to its robust liquidity profile. The absence of long-term debt further enhances its financial flexibility, as reflected in a debt-to-equity ratio of 0.

    In terms of profitability, the company's return on equity (ROE) is 4.02%, and its return on assets (ROA) is 1.22%. These figures suggest that the company is generating modest returns relative to its equity and total assets. While the ROE is in line with the industry's typical performance, the ROA is relatively low, indicating that the company may not be efficiently utilizing its assets to generate profit.

    The company's revenue is concentrated in a single business segment, as no specific segments are disclosed. Geographically, the company's exposure is primarily within Vietnam, with no significant international operations reported. This concentration may pose a risk if the domestic real estate market experiences a downturn.

    Thong Nhat JSC's growth trajectory is supported by its operating income of VND 11.06 billion and net income of VND 8.83 billion. The company's capital expenditures were negative at VND -6.24 billion, suggesting a reduction in investment in new projects or assets. This could indicate a strategic shift or a response to market conditions.

    The company's risk assessment indicates low liquidity and dilution risks. There are no immediate filing-based liquidity or dilution flags, and the absence of long-term debt reduces the likelihood of financial distress. The dilution potential is also low, with no significant changes in shares outstanding between basic and diluted figures.

    Recent events and filings do not indicate any material changes in the company's operations or financial position. The company's operating cash flow of VND 22.41 billion and free cash flow of VND 3.72 billion suggest a healthy cash generation capability, supporting its current operations and potential for future growth.

    Key takeaways
    • Thong Nhat JSC has a strong liquidity position with a current ratio of 7.43 and no long-term debt.
    • The company's ROE of 4.02% is modest, and its ROA of 1.22% indicates inefficient asset utilization.
    • Revenue and operations are concentrated in a single segment and domestic market, posing concentration risk.
    • The company's capital expenditures were negative, suggesting a strategic shift or reduced investment.
    • Low liquidity and dilution risks are supported by strong cash flow and no immediate filing-based flags.

    Bull / Bear case

    Generated · model-assisted
    BULL CASE · 5

    Operating and net margins significantly exceed the real estate cohort median, indicating superior profitability relative to peers.

    The company maintains zero long-term debt, providing a strong balance sheet with no leverage risk compared to peers.

    Revenue grew 51% year-over-year in the latest period, demonstrating strong top-line momentum despite historical volatility.

    Free cash flow turned positive in the latest period, reversing a multi-year trend of negative cash generation.

    Return on equity exceeds the cohort median, suggesting efficient use of shareholder capital despite low absolute levels.

    BEAR CASE · 5

    Revenue and net income declined over the four-year CAGR period, indicating a long-term downward trend in business scale.

    Return on assets and return on invested capital are extremely low, signaling inefficient capital deployment relative to book value.

    Capital expenditure as a percentage of revenue is in the bottom quartile, potentially limiting future growth capacity.

    Free cash flow was negative for four of the last five periods, highlighting inconsistent cash generation capabilities.

    The latest revenue figure remains significantly below the peak recorded in FY-4, suggesting the business has not fully recovered.

    In focus — financials by report

    Valuation FY

    Market price
    $1,53
    Market cap
    Enterprise value
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    P / Tangible book
    Tangible book
    $219.48B
    Net cash
    $22.80B
    Current ratio
    7.4
    Debt / equity
    0.0
    ROA
    1.2%
    ROE
    4.0%
    Cash conversion
    254.0%
    CapEx / revenue
    -33.4%
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    INDUSTRYSEGMENTCOMPANYHealthcareIndustryDiversified Medical Equipment & Supplies259,3B node revenueABT 17,1%MDT 14,0%MDLN 11,0%SYK 9,7%BDX 8,4%HSIC 5,1%BAX 4,3%SOLV 3,2%Other 27,2%
    Source: company disclosures · own-taxonomy revenue-covered set · attribution: collision-suspect (indicative)BAX 4,3% · rank #7 of 84

    Business relationships

    Business relationships36 disclosed relationships · 2 types · extracted from filings & disclosures
    Subsidiaries33
    EX21:050a5a129d52EX21:050a5a129d52Subsidiarie97%
    EX21:0ee29af46bc0EX21:0ee29af46bc0Subsidiarie97%
    EX21:0f62fc61fa45EX21:0f62fc61fa45Subsidiarie97%
    EX21:1495cf2238c0EX21:1495cf2238c0Subsidiarie97%
    EX21:162906db8345EX21:162906db8345Subsidiarie97%
    EX21:188031cc7c1eEX21:188031cc7c1eSubsidiarie97%
    EX21:30e4556dbe77EX21:30e4556dbe77Subsidiarie97%
    EX21:3910099c123dEX21:3910099c123dSubsidiarie97%
    EX21:3a548053cbcdEX21:3a548053cbcdSubsidiarie97%
    EX21:4091e6d9e637EX21:4091e6d9e637Subsidiarie97%
    EX21:45f74803765bEX21:45f74803765bSubsidiarie97%
    EX21:49d7aca880efEX21:49d7aca880efSubsidiarie97%
    EX21:4ba24648f600EX21:4ba24648f600Subsidiarie97%
    EX21:5f0d6e374ad3EX21:5f0d6e374ad3Subsidiarie97%
    EX21:621dbe135c44EX21:621dbe135c44Subsidiarie97%
    EX21:6c8f478bd8c8EX21:6c8f478bd8c8Subsidiarie97%
    EX21:84837b35236cEX21:84837b35236cSubsidiarie97%
    EX21:861586c376f7EX21:861586c376f7Subsidiarie97%
    EX21:8f9c233a92faEX21:8f9c233a92faSubsidiarie97%
    EX21:91e8ed0c3135EX21:91e8ed0c3135Subsidiarie97%
    EX21:9f7157742b70EX21:9f7157742b70Subsidiarie97%
    EX21:aaa1c8b1e2f4EX21:aaa1c8b1e2f4Subsidiarie97%
    EX21:b0f04d171676EX21:b0f04d171676Subsidiarie97%
    EX21:b9cdb0c9f920EX21:b9cdb0c9f920Subsidiarie97%
    EX21:bd2e02edfaadEX21:bd2e02edfaadSubsidiarie97%
    EX21:be846a03d5bcEX21:be846a03d5bcSubsidiarie97%
    EX21:c13bca3a53b0EX21:c13bca3a53b0Subsidiarie97%
    EX21:d59e2eaecd97EX21:d59e2eaecd97Subsidiarie97%
    EX21:dc1a6882e6e9EX21:dc1a6882e6e9Subsidiarie97%
    EX21:e6f6f8a98ddaEX21:e6f6f8a98ddaSubsidiarie97%
    EX21:ea73c2cfbba1EX21:ea73c2cfbba1Subsidiarie97%
    EX21:edd797171e32EX21:edd797171e32Subsidiarie97%
    EX21:f2e47e27b0b1EX21:f2e47e27b0b1Subsidiarie97%
    Competitors3
    Bank Of America CorpBAC.OCompetitor50%
    CITIGROUP INC.C.NCompetitor50%
    JPMORGAN CHASE & CO.JPM.NCompetitor50%

    Supply chain

    — missing data

    Peer comparison

    Peer comparison7 peers · vs BAX · multiples and returns
    AB
    ABT
    Abbott Laboratories
    $107,13
    187,2B USD
    P/E
    26,3x
    vs self
    Div yield
    2,4 %
    +0,2 vs self
    ROE
    12,5 %
    +27,9 vs self
    MD
    MDT
    Medtronic PLC
    $86,19
    110,3B USD
    P/E
    21,4x
    vs self
    Div yield
    3,4 %
    +1,1 vs self
    ROE
    9,7 %
    +25,1 vs self
    MD
    MDLN
    MEDLINE INC.
    $40,47
    53,2B USD
    P/E
    202,6x
    vs self
    Div yield
    vs self
    ROE
    vs self
    SY
    SYK
    Stryker Corp
    $341,20
    131,8B USD
    P/E
    38,0x
    vs self
    Div yield
    vs self
    ROE
    13,5 %
    +28,9 vs self
    BD
    BDX
    Becton Dickinson And Co
    $170,21
    48,4B USD
    P/E
    25,6x
    vs self
    Div yield
    2,8 %
    +0,5 vs self
    ROE
    7,0 %
    +22,4 vs self
    HS
    HSIC
    Henry Schein Inc
    $88,21
    10,1B USD
    P/E
    80,5x
    vs self
    Div yield
    vs self
    ROE
    3,0 %
    +18,4 vs self
    SO
    SOLV
    SOLVENTUM CORPORATION
    $76,83
    13,3B USD
    P/E
    8,6x
    vs self
    Div yield
    vs self
    ROE
    30,8 %
    +46,2 vs self

    Market position

    Stress test

    — missing data

    Predictor forecast

    Next quarternear-term
    Earnings · next quarterconf 45 %
    EPS
    Consensus EPS
    1,92
    Predicted surprise
    +0,08
    Beat probability
    45 %
    Analysts
    17
    Other metrics
    Revenue
    no estimate
    Segment revenue
    no estimate
    Margin
    no estimate
    Segment margin
    no estimate
    revision ratio 0,00 · as of 2026-07-10 · Earnings Surprise V1
    Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.
    Corporate eventM&A horizon
    M&A probabilityconf 3 %
    Probability
    3 %
    Base rate
    3 %
    Band
    180-day horizon · target 2027-01-31 · 1,0× base rate
    No acquirer candidates identified by the signal model.
    Probabilistic model output — not investment advice. · generated 2026-08-04

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    Low$15,00
    Mean$21,19
    Median$19,00
    High$42,21
    Spot$1,53
    +1285.2 %implied to mean12-month sell-side price targets · ▲ spot

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskLow
    Filing-based flags
    • No immediate filing-based liquidity or dilution flags were detected.

    Benchmarks vs cohort

    Op Margin59,2 %Best in class
    Net Margin47,3 %Best in class
    ROE4,0 %Above median
    Capex / Rev-33,4 %Bottom quartile
    D/E0,00Above median
    Cash Conv2,54Above P75

    Corporate actions / M&A

    M&A probabilityconf —
    Probability
    3 %
    Base rate
    3 %
    Band
    Low
    180-day horizon · target 2027-01-31 · 1,0× base rate
    No acquirer candidates identified by the signal model.
    Corporate actionsNo corporate-action source connected yet — splits, dividends and buyback events are not tracked for this company. Honest-dim (no data fabricated).

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    Derivative transactions

    Net acquired 757 183 sh5 grants5 insiders
    • Carlisle CynthiaExecutive Vice President, CHRO · Stock Option (Right to Buy) → Common Stock, $1 par valueAcquired 43 103 @ $20,37grant · 2026-02-27
    • Rosenbloom David S.EVP and General Counsel · Stock Option (Right to Buy) → Common Stock, $1 par valueAcquired 64 655 @ $20,37grant · 2026-02-27
    • Grade Joel T.EVP and CFO · Stock Option (Right to Buy) → Common Stock, $1 par valueAcquired 103 448 @ $20,37grant · 2026-02-27
    • Hider Andrew P.Director, President and CEO · Stock Option (Right to Buy) → Common Stock, $1 par valueAcquired 488 506 @ $20,37grant · 2026-02-27
    • Soriano Maria CeciliaGroup Pres., ITT & Pharma. · Stock Option (Right to Buy) → Common Stock, $1 par valueAcquired 57 471 @ $20,37grant · 2026-02-27

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Capex To Revenue
      capital_expenditure / revenue
    • Return On Equity
      net_income / total_equity
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    Source documents
    • Thong Nhat JSC Market data — financials · 2026-05-27

    Ownership & reference

    Top holders

    • Dodge & CoxInvestment Managers · as of 2026-03-310,53 %$962M
    • BlackRock Institutional Trust Company, N.A.Investment Managers · as of 2024-06-300,05 %$2 109M
    • FMR LLCInstitutional Investor · as of 2026-03-310,04 %$777M
    • Invesco QQQ TrustFunds · as of 2026-03-310,03 %$220M
    • EATON VANCE MANAGEMENTInstitutional Investor · as of 2022-09-300,03 %$0M
    • Dimensional Fund Advisors, L.P.Investment Managers · as of 2026-03-310,02 %$100M
    • Vanguard Capital Management, LLCInvestment Managers · as of 2025-12-310,02 %$1 197M
    • Geode Capital Management, L.L.C.Investment Managers · as of 2026-03-310,01 %$231M
    • Charles Schwab Investment Management, Inc.Investment Managers · as of 2026-03-310,01 %$94M
    • UBS Financial Services, Inc.Investment Managers · as of 2026-03-310,01 %$73M
    • State Street Investment Management (US)Investment Managers · as of 2026-03-310,01 %$336M
    • JONES FINANCIAL COMPANIES LLLPInstitutional Investor · as of 2026-03-310,01 %$24M
    • Raymond James & Associates, Inc.Brokerage Firms · as of 2026-03-310,01 %$33M
    • Northern Trust Investments, Inc.Investment Managers · as of 2026-03-310,01 %$73M
    • Nuveen LLCInvestment Managers · as of 2024-12-310,01 %$30M
    • Goldman Sachs Asset Management, L.P.Investment Managers · as of 2026-03-310,01 %$65M
    • Bank of New York Mellon CorpInstitutional Investor · as of 2026-03-310,01 %$44M
    • Morgan Stanley Smith Barney LLCInvestment Managers · as of 2026-03-310,01 %$123M
    • Principal Global Investors (Equity)Investment Managers · as of 2026-03-310,01 %$10M
    • AQR Capital Management, LLCInvestment Managers · as of 2026-03-310,00 %$9M
    • First Trust Advisors L.P.Investment Managers · as of 2026-03-310,00 %$5M
    • AllianceBernstein L.P.Investment Managers · as of 2026-03-310,00 %$10M
    • Victory Capital Management Inc.Investment Managers · as of 2026-03-310,00 %$5M
    • Wells Fargo AdvisorsBrokerage Firms · as of 2026-03-310,00 %$15M
    • JANUS HENDERSON GROUP PLCInstitutional Investor · as of 2026-03-310,00 %$4M
    • PNC Investments LLCInvestment Managers · as of 2026-03-310,00 %$3M
    • T. Rowe Price Associates, Inc.Investment Managers · as of 2026-03-310,00 %$0M
    • LPL Financial LLCInvestment Managers · as of 2026-03-310,00 %$3M
    • American Century Investment Management, Inc.Investment Managers · as of 2026-03-310,00 %$1M
    • PNC Investments LLCInvestment Managers · as of 2026-03-310,00 %$1M
    • AMERIPRISE FINANCIAL INCInstitutional Investor · as of 2026-03-310,00 %$2M
    • Franklin Advisers, Inc.Investment Managers · as of 2026-03-310,00 %$0M
    • Wellington Management Company, LLPInvestment Managers · as of 2026-03-310,00 %$1M
    • JONES FINANCIAL COMPANIES LLLPInstitutional Investor · as of 2026-03-310,00 %$0M

    Insider activity

    Mixed / flat0 buys · 0 sellsnet $017 insiders · last 365d
    • Wallace Steven P.President, Adv. Surgery · Common Stock, $1 par valueOther 153 @ $18,68$3K · 2026-06-02
    • Teaff JamesPresident, CCS · Common Stock, $1 par valueOther 321 @ $18,68$6K · 2026-06-02
    • Zielinski Anita ASVP, Interim CFO, CAO & Cntrlr · Common Stock, $1 par valueOther 13 426 · 2026-06-01
    • Wendell Amy McBrideDirector · Common Stock, $1 par valueOther 12 836 · 2026-05-05
    • Wilkes David S.Director · Common Stock, $1 par valueOther 12 836 · 2026-05-05
    • Ampofo William A. IIDirector · Common Stock, $1 par valueOther 12 836 · 2026-05-05
    • Craig Jeffrey ADirector · Common Stock, $1 par valueOther 12 836 · 2026-05-05
    • McDonnell Michael R.Director · Common Stock, $1 par valueOther 12 836 · 2026-05-05
    • Shafer David BrentDirector, Chair of the Board · Common Stock, $1 par valueOther 12 836 · 2026-05-05
    • MORRISON PATRICIADirector · Common Stock, $1 par valueOther 12 836 · 2026-05-05
    • SCHLICHTING NANCY MDirector · Common Stock, $1 par valueOther 12 836 · 2026-05-05
    • Grade Joel T.EVP and CFO · Common Stock, $1 par valueOther 8 153 @ $17,69$144K · 2026-03-06
    • Rosenbloom David S.EVP and General Counsel · Common Stock, $1 par valueOther 6 620 @ $17,69$117K · 2026-03-06
    • Soriano Maria CeciliaGroup Pres., ITT & Pharma. · Common Stock, $1 par valueOther 2 848 @ $17,69$50K · 2026-03-06
    • Zielinski Anita ASVP, CAO and Controller · Common Stock, $1 par valueOther 1 932 @ $17,69$34K · 2026-03-06
    • Rasul ReazurEVP,Group Pres,Healthcare · Common Stock, $1 par valueOther 12 674 @ $17,69$224K · 2026-03-06
    • Rosenbloom David S.EVP and General Counsel · Common Stock, $1 par valueOther 1 336 @ $19,69$26K · 2026-03-02
    • Rasul ReazurEVP,Group Pres,Healthcare · Common Stock, $1 par valueOther 1 614 @ $19,69$32K · 2026-03-02
    • Soriano Maria CeciliaGroup Pres., ITT & Pharma. · Common Stock, $1 par valueOther 1 852 @ $19,69$36K · 2026-03-02
    • Grade Joel T.EVP and CFO · Common Stock, $1 par valueOther 42 735 · 2026-02-27
    • Carlisle CynthiaExecutive Vice President, CHRO · Common Stock, $1 par valueOther 17 806 · 2026-02-27
    • Hider Andrew P.Director, President and CEO · Common Stock, $1 par valueOther 201 804 · 2026-02-27
    • Carlisle CynthiaExecutive Vice President, CHRO · Common Stock, $1 par valueOther 11 871 · 2026-02-27
    • Rosenbloom David S.EVP and General Counsel · Common Stock, $1 par valueOther 26 709 · 2026-02-27
    • Soriano Maria CeciliaGroup Pres., ITT & Pharma. · Common Stock, $1 par valueOther 23 742 · 2026-02-27

    Short positioning

    36.8Mshares short-4.5% vs prior
    6.52days to cover
    56.9%short of daily vol
    1.7Kfails-to-deliver
    as of 2026-07-15 · short-interest report (free)
    Index membership
    S&P 500United States

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    BAX.HNCanonical
    — · USD

    Intel & risk

    PredictorBeat prob45 %Surprise+0,08M&A prob3 %Full forecast →
    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskLow
    No immediate filing-based liquidity or dilution flags were detected.
    Relationship graph
    BAXEX21:050EX21:0eeEX21:0f6EX21:149EX21:162EX21:188EX21:30eEX21:391EX21:3a5EX21:409Diversified Me
    This companySectorSubsidiaries

    Evidence & claims

    From filings & derived data
    • R&D expense (YoY) (2025-12-31 vs 2024-12-31): -12.2%Derived (calculated)
    • EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): -47.2%Derived (calculated)
    • Total liabilities (YoY) (2025-12-31 vs 2024-12-31): -25.6%Derived (calculated)
    • Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): -12.0%Derived (calculated)
    • Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): 11.5%Derived (calculated)
    • Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): -17.1%Derived (calculated)
    • Debt-to-equity (FY 2025-12-31): 2.28xDerived (calculated)
    • EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): -47.2%Derived (calculated)
    • Total assets (YoY) (2025-12-31 vs 2024-12-31): -22.2%Derived (calculated)
    • Current ratio (FY 2025-12-31): 2.31xDerived (calculated)
    • Return on assets (FY 2025-12-31): -4.8%Derived (calculated)
    • Return on equity (FY 2025-12-31): -15.6%Derived (calculated)
    • Gross margin (FY 2025-12-31): 30.1%Derived (calculated)
    • Operating income (YoY) (2025-12-31 vs 2024-12-31): -2,300.0%Derived (calculated)
    • Net income (YoY) (2025-12-31 vs 2024-12-31): -47.5%Derived (calculated)
    • Cost of revenue (YoY) (2025-12-31 vs 2024-12-31): 18.2%Derived (calculated)
    • Net margin (FY 2025-12-31): -8.5%Derived (calculated)
    • Long-term debt (YoY) (2025-12-31 vs 2024-12-31): -28.4%Derived (calculated)
    • Gross profit (YoY) (2025-12-31 vs 2024-12-31): -15.2%Derived (calculated)
    • Revenue (YoY) (2025-12-31 vs 2024-12-31): 5.7%Derived (calculated)
    • Operating cash flow (annual): USD 845MSEC XBRL filing
    • R&D expense (annual): USD 518MSEC XBRL filing
    • Gross profit (annual): USD 3.38BSEC XBRL filing
    • Pre-tax income (annual): USD -505MSEC XBRL filing
    Showing 24 of 60 surfaced claims.
    Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.

    The Thread

    Everything we know, in order
    2026-09-09EVENTUpcomingQ2 2026 earnings (confirmed · filed)
    2026-07-31 04:36 UTCFILINGMaterial 8-K
    2026-07-30EVENTQ2 2026 earnings (expected) estimated date
    2026-07-03 03:12 UTCHOLDERInstitutional holding changed
    2026-07-03 03:12 UTCHOLDER1 institutional position change flagged (1 major)
    2026-07-02 03:15 UTCHOLDERInstitutional holding changed
    2026-07-02 03:15 UTCHOLDER1 institutional position change flagged (1 major)
    2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)
    2026-06-30 03:38 UTCEARNINGSUpcomingForecast: ma_probability (180d)
    2026-06-28 03:14 UTCHOLDERInstitutional holding changed
    2026-06-28 03:14 UTCHOLDERInstitutional holding changed
    2026-06-28 03:14 UTCHOLDER2 institutional position changes flagged (2 major)
    2026-06-27 03:14 UTCHOLDERInstitutional holding changed
    2026-06-27 03:14 UTCHOLDER1 institutional position change flagged (1 major)
    2026-06-25 03:10 UTCHOLDERInstitutional holding changed
    2026-06-25 03:10 UTCHOLDER1 institutional position change flagged (1 major)
    2026-06-23 03:11 UTCHOLDERInstitutional holding changed
    2026-06-23 03:11 UTCHOLDER1 institutional position change flagged (1 major)
    2026-06-02 00:00 UTCINSIDER3 insider transactions — 2026-06
    2026-06-02 00:00 UTCINSIDER3 insider transactions — 2026-06
    2026-06-02INSIDERWallace Steven P. transacted 153 sh Common Stock, $1 par value — President, Adv. Surgery ~$3k
    2026-06-02INSIDERTeaff James transacted 321 sh Common Stock, $1 par value — President, CCS ~$6k
    2026-06-01INSIDERZielinski Anita A transacted 13.4k sh Common Stock, $1 par value — SVP, Interim CFO, CAO & Cntrlr
    2026-05-08FILING8-K filing →
    2026-05-05 00:00 UTCINSIDER8 insider transactions — 2026-05
    2026-05-05 00:00 UTCINSIDER8 insider transactions — 2026-05
    2026-05-05INSIDERWendell Amy McBride transacted 12.8k sh Common Stock, $1 par value — Director
    2026-05-05INSIDERWilkes David S. transacted 12.8k sh Common Stock, $1 par value — Director
    2026-05-05INSIDERAmpofo William A. II transacted 12.8k sh Common Stock, $1 par value — Director
    2026-05-05INSIDERCraig Jeffrey A transacted 12.8k sh Common Stock, $1 par value — Director
    2026-05-05INSIDERMcDonnell Michael R. transacted 12.8k sh Common Stock, $1 par value — Director
    2026-05-05INSIDERShafer David Brent transacted 12.8k sh Common Stock, $1 par value — Director, Chair of the Board
    2026-05-05INSIDERMORRISON PATRICIA transacted 12.8k sh Common Stock, $1 par value — Director
    2026-05-05INSIDERSCHLICHTING NANCY M transacted 12.8k sh Common Stock, $1 par value — Director
    2026-05-01 11:54 UTCFILINGRegulatory filing →
    2026-04-30FILING10-Q filing →
    2026-04-30FILING8-K filing →
    2026-03-23FILINGDEF 14A filing →
    2026-03-19FILING8-K filing →
    2026-03-16FILING8-K filing →
    Showing the 40 most recent of 77 entries.
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage